IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights
Provided By GlobeNewswire
Last update: Aug 13, 2024
NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today reported financial results for the second quarter ended June 30, 2024.
Read more at globenewswire.com
